Science Class Starts Early If You Have An Autoimmune Disease Like Type 1 Diabetes (T1D)
Navacims Are Breakthrough Science For Autoimmune Disease
Navacims Are Nanoparticles Coated With Immune System Proteins To Fight Disease
Navacims Can Be Tailored To Different Diseases Including T1D, Multiple Sclerosis & Arthritis
NavacimTD In Development So That People With T1D Can Forget About Science And Just Be . . .
Welcome
Parvus is a privately held biopharmaceutical company developing and commercializing a nanotechnology-based therapeutic platform for the treatment of autoimmunity.
We believe that our therapeutic candidates, Navacims, have the potential to radically improve the lives of patients with autoimmune disease. Navacims, are nanoparticles conjugated to immune system proteins that can be readily modified to target a range of autoimmune conditions like type I diabetes (T1D), multiple sclerosis and rheumatoid arthritis, amongst others. Our lead candidate, NavacimTD, is in development for T1D.
Our Team
-
President & CEO
Phil Coggins joined Parvus on 25 May 2011, World MS Day, with more than 25 years in life science research and the biotech industry. -
Chief Scientific Officer
Pere Santamaria, an internationally recognized leader in diabetes research, is the scientific founder of Parvus. -
Business Development
Jord Cowan is part of the company creation team at UTI.ca and was instrumental in getting Parvus off the ground.